Similarly, in the analysis by cancer subtypes, the VDR BsmI rs1544410-AA genotype significantly reduced the risk of developing NSCLC (p < 0.00001; OR = 0.41; CI95% = 0.29–0.58; I2 = 56%; pheterogeneity = 0.06; A vs. G and p = 0.0004; OR = 0.22; CI95% = 0.10–0.51; I2 = 0%; pheterogeneity = 0.76; AA vs. G) [28]. This evidence concerns the gene VDR and cancer.